In the human AD brain, there is an increase in the expression of SPL coupled with a reduction of S1P synthetic enzyme SphK1, by implication low S1P levels, which correlates with amyloid deposits in the entorhinal cortex [15], the gateway to the hippocampus and affected in an early stage of AD. This evidence concerns the gene SPHK1 and Alzheimer disease.